Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Gains from Investment Securities: 2019-2021

Historic Gains from Investment Securities for Avidity Biosciences (RNA) over the last 1 years, with Dec 2021 value amounting to $12.1 million.

  • Avidity Biosciences' Gains from Investment Securities rose 4537.69% to $12.1 million in Q4 2021 from the same period last year, while for Sep 2021 it was $5.6 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2023, which is N/A change from last year.
  • As of Q4 2021, Avidity Biosciences' Gains from Investment Securities stood at $12.1 million, which was up 113.45% from $5.6 million recorded in Q3 2021.
  • Over the past 5 years, Avidity Biosciences' Gains from Investment Securities peaked at $12.1 million during Q4 2021, and registered a low of $260,000 during Q4 2020.
  • Moreover, its 3-year median value for Gains from Investment Securities was $5.5 million (2021), whereas its average is $4.7 million.
  • Data for Avidity Biosciences' Gains from Investment Securities shows a peak YoY surged of 4,537.69% (in 2021) over the last 5 years.
  • Over the past 3 years, Avidity Biosciences' Gains from Investment Securities (Quarterly) stood at $811,000 in 2019, then skyrocketed by 252.90% to $260,000 in 2020, then surged by 4,537.69% to $12.1 million in 2021.
  • Its Gains from Investment Securities stands at $12.1 million for Q4 2021, versus $5.6 million for Q3 2021 and $5.8 million for Q2 2021.